A true health check for every European citizen. All EU-authorized medicines in the European Union must be tested for the presence of nitrosamines, carcinogens based on AIFa withdrawal from the ranitidine series and which in 2018 also caused the withdrawal of many valsartan-containing antihypertensive drugs. . This request comes from the European Medicines Agency (EMA). The reason for this resolution, says Emma, is caution and applies to all drugs containing active ingredients produced by chemical synthesis.
"If nitrosamines are found in one of these drugs – the law states – the marketing authorization holder must promptly notify the authorities to take the most appropriate regulatory measures." Nitrosamines are classified as likely carcinogens so exposure above safe levels may increase the risk of long-term cancer. "They are present in some foods and in drinking water – adds Emma – and when they were found in drugs, the risk of developing a tumor was assessed as low."